Qlaris Bio, Inc., a biotechnology firm focusing on ophthalmic diseases, has announced the initiation of two Phase II clinical trials in the U.S. to investigate QLS‑111, a pioneering treatment for patients with ocular hypertension and glaucoma. This first-in-class product targets episcleral venous pressure (EVP) to achieve intraocular pressure (IOP) reductions beyond current possibilities. The commencement of these trials represents a significant step towards addressing the unmet needs of glaucoma patients requiring consistent IOP control.
QLS‑111 is distinguished by its unique mechanism that reduces IOP by targeting EVP and distal outflow resistance, offering potential benefits for patients with primary open-angle glaucoma (POAG), ocular hypertension (OHT), and normal tension glaucoma (NTG). Unlike existing medications that either decrease aqueous humor production or enhance proximal outflow, QLS‑111 directly impacts distal outflow and EVP, a critical factor constituting up to 50% of total IOP.
The promise of QLS‑111 is highlighted by its capability to lower IOP significantly from baseline in healthy, normotensive volunteers, as well as its compatibility with existing glaucoma treatments. This suggests that QLS‑111 could offer a synergistic advantage in achieving IOP reductions necessary for slowing disease progression. Given its favorable safety profile and lack of clinically meaningful hyperemia, QLS‑111 shows immense potential as a flexible addition to current glaucoma therapy regimens.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
